Beta-thalassemia history and symptoms: Difference between revisions
Jump to navigation
Jump to search
| Line 22: | Line 22: | ||
*Hormonal imbalances | *Hormonal imbalances | ||
*Cognitive problems | *Cognitive problems | ||
Intermedia variant patients might experience moderate anemia, splenomegaly, bone changes, and intermittent need for blood transfusions at different ages<ref name="pmid32557398">{{cite journal |vauthors=Motta I, Bou-Fakhredin R, Taher AT, Cappellini MD |title=Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation |journal=Drugs |volume=80 |issue=11 |pages=1053–1063 |date=July 2020 |pmid=32557398 |doi=10.1007/s40265-020-01341-9 |url=}}</ref><ref name="pmid34738740">{{cite journal |vauthors=Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi SAR, Sadia, Irfan M, Khan MA |title=Current status of beta-thalassemia and its treatment strategies |journal=Mol Genet Genomic Med |volume=9 |issue=12 |pages=e1788 |date=December 2021 |pmid=34738740 |pmc=8683628 |doi=10.1002/mgg3.1788 |url=}}</ref> | Intermedia variant patients might experience moderate anemia, splenomegaly, bone changes, and intermittent need for blood transfusions at different ages<ref name="pmid32557398">{{cite journal |vauthors=Motta I, Bou-Fakhredin R, Taher AT, Cappellini MD |title=Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation |journal=Drugs |volume=80 |issue=11 |pages=1053–1063 |date=July 2020 |pmid=32557398 |doi=10.1007/s40265-020-01341-9 |url=}}</ref><ref name="pmid34738740">{{cite journal |vauthors=Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi SAR, Sadia, Irfan M, Khan MA |title=Current status of beta-thalassemia and its treatment strategies |journal=Mol Genet Genomic Med |volume=9 |issue=12 |pages=e1788 |date=December 2021 |pmid=34738740 |pmc=8683628 |doi=10.1002/mgg3.1788 |url=}}</ref><ref name="pmid31030806">{{cite journal |vauthors=Khandros E, Kwiatkowski JL |title=Beta Thalassemia: Monitoring and New Treatment Approaches |journal=Hematol Oncol Clin North Am |volume=33 |issue=3 |pages=339–353 |date=June 2019 |pmid=31030806 |doi=10.1016/j.hoc.2019.01.003 |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 20:18, 16 August 2023
|
Beta-thalassemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Beta-thalassemia history and symptoms On the Web |
|
American Roentgen Ray Society Images of Beta-thalassemia history and symptoms |
|
Risk calculators and risk factors for Beta-thalassemia history and symptoms |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]
Overview
History and Symptoms
Major variant patients present in early infancy with:
- Severe anemia
- Failure to thrive
- Pallor
- Jaundice
- Fatigue
- Growth retardation
After treatment initiation, they would have symptoms of iron overload due to multiple transfusions which may cause:
- Fatigue and weakness
- Arthritis
- Abdominal pain
- Bronzed or grayish skin
- Loss of libido
- Hormonal imbalances
- Cognitive problems
Intermedia variant patients might experience moderate anemia, splenomegaly, bone changes, and intermittent need for blood transfusions at different ages[1][2][3]
References
- ↑ Motta I, Bou-Fakhredin R, Taher AT, Cappellini MD (July 2020). "Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation". Drugs. 80 (11): 1053–1063. doi:10.1007/s40265-020-01341-9. PMID 32557398 Check
|pmid=value (help). - ↑ Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi S, Sadia, Irfan M, Khan MA (December 2021). "Current status of beta-thalassemia and its treatment strategies". Mol Genet Genomic Med. 9 (12): e1788. doi:10.1002/mgg3.1788. PMC 8683628 Check
|pmc=value (help). PMID 34738740 Check|pmid=value (help). Vancouver style error: initials (help) - ↑ Khandros E, Kwiatkowski JL (June 2019). "Beta Thalassemia: Monitoring and New Treatment Approaches". Hematol Oncol Clin North Am. 33 (3): 339–353. doi:10.1016/j.hoc.2019.01.003. PMID 31030806.